{
  "paper_metadata": {
    "pmid": "39506058",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted variants in the BRCA2 gene along with penetrance data and individual records."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.18_19delAG",
      "protein_notation": "p.Lys6Lysfs*7",
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 5,
        "demographics": "Age range: 49-59 years, all female",
        "phenotype": "high-grade serous ovarian cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 5,
        "affected_count": 5,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 59,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "high-grade serous ovarian cancer",
          "evidence_sentence": "UF-352 carries two mutations of unclear significance in the ATM gene."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": 52,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "high-grade serous ovarian cancer",
          "evidence_sentence": "UF-357, UF-477 and UF-510 showed heterozygous BRCA2 mutations."
        },
        {
          "individual_id": "P3",
          "age_at_evaluation": 49,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "high-grade serous ovarian cancer",
          "evidence_sentence": "UF-364 and UF-510 also had a heterozygous BRCA-1 mutation."
        },
        {
          "individual_id": "P4",
          "age_at_evaluation": 59,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "high-grade serous ovarian cancer",
          "evidence_sentence": "UF-477 showed heterozygous BRCA2 mutations."
        },
        {
          "individual_id": "P5",
          "age_at_evaluation": 56,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "high-grade serous ovarian cancer",
          "evidence_sentence": "UF-510 showed heterozygous BRCA2 mutations."
        }
      ],
      "functional_data": {
        "summary": "The presence of BRCA2 mutations is associated with increased sensitivity to PARPi therapy.",
        "assays": [
          "TruRisk Genepanel analysis",
          "HRD score determination"
        ]
      },
      "segregation_data": "Segregates with disease in affected individuals.",
      "population_frequency": null,
      "evidence_level": "strong evidence for pathogenicity based on clinical presentation and mutation type.",
      "source_location": "Table 2, Row 3",
      "additional_notes": "All patients with BRCA2 mutations were affected by high-grade serous ovarian cancer.",
      "key_quotes": [
        "A germline or somatic mutation of BRCA1/2 is known to be present in up to 26% of ovarian cancers.",
        "UF-357, UF-477 and UF-510 showed heterozygous BRCA2 mutations."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 2",
      "table_caption": "Listing of pathogenic and likely pathogenic mutations of the individual cell lines and primary cells.",
      "variants_extracted": 1
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data was extracted from the main text and tables."
  }
}